Ashley Hall's most recent trade in Structure Therapeutics Inc - ADR was a trade of 124,032 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Structure Therapeutics Inc | Ashley F. Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 124,032 | 124,032 | - | - | Employee Stock Option (right to buy) | |
| Structure Therapeutics Inc | Ashley F. Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 51,048 | 118,338 | - | 0 | Ordinary Shares | |
| Structure Therapeutics Inc | Ashley F. Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 82,890 | 82,890 | - | - | Share option (right to buy) | |
| Structure Therapeutics Inc | Ashley F. Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 67,290 | 67,290 | - | 0 | Ordinary Shares | |
| Reneo Pharmaceuticals Inc | Ashley Hall | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2023 | 15,625 | 109,375 | - | - | Stock option (right to buy) | |
| Reneo Pharmaceuticals Inc | Ashley Hall | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 6.28 per share. | 28 Aug 2023 | 15,625 | 39,600 | - | 6.3 | 98,058 | Common Stock |
| Reneo Pharmaceuticals Inc | Ashley Hall | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.80 per share. | 28 Aug 2023 | 15,625 | 55,225 | - | 1.8 | 28,125 | Common Stock |
| Reneo Pharmaceuticals Inc | Ashley Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 125,000 | 125,000 | - | - | Stock option (right to buy) | |
| Reneo Pharmaceuticals Inc | Ashley Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Ashley Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 30,000 | 30,000 | - | 0 | Common Stock | |
| Esperion Therapeutics Inc | Ashley Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 31,000 | 31,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc | Ashley Hall | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 7,000 | 22,500 (0%) | 0% | 0 | Common Stock |